Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

CC-486 Improves Transfusion Independence in MDS, but Adverse Events Are Common

For patients with lower-risk myelodysplastic syndromes (MDS) and both red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia, CC-486, an oral formulation of the hypomethylating...
On location

ENDURANCE: Comparing KRd With VRd in Newly Diagnosed Myeloma

Initial treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) was not associated with longer progression-free survival (PFS) compared with bortezomib, lenalidomide, and dexamethasone (VRd) in...
On location

DVT Increases Health-Care Burden and Mortality in Patients with Cancer

Patients with cancer and deep vein thrombosis (DVT) experience higher rates of hospitalization and mortality, are less frequently treated with thrombolysis, and experience gastrointestinal...
On location

BCMA Bispecific Antibody “Promising” for Relapsed or Refractory Myeloma

Interim results from a phase I dose-finding study suggest that CC-93269, a bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells...
On location

KEYNOTE-204: Pembrolizumab Superior to Brentuximab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with anti-PD-1 antibody pembrolizumab prolonged progression-free survival (PFS) more than brentuximab vedotin (BV) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R...
On location

Examining PTSD Symptoms in Patients Undergoing HCT

When patients undergo hematopoietic cell transplantation (HCT), they are usually hospitalized and isolated for a prolonged period and may experience a substantial physical and...
On location

ASPEN: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with the selective Bruton tyrosine kinase (BTK) inhibitor zanubrutinib resulted in a higher combined complete response (CR) and very good partial response (VGPR)...
On location

CRISPR-Based Therapy Targeting BCL11 Shows Clinical Benefit in SCD and Beta-Thalassemia

Treatment with the CRISPR/Cas9 gene-editing therapy CTX001 was associated with successful neutrophil and platelet engraftment in 2 patients with transfusion-dependent β-thalassemia (TDT) and 1...
On location

Interim Results of Randomized Comparison of Ponatinib Starting Doses in Chronic-Phase CML

Response-based ponatinib dosing demonstrated clinical benefit in patients with resistant chronic-phase chronic myeloid leukemia (CML) with rate of arterial occlusive (AO) events that did...
On location

BOSTON: Weekly Combination Therapy Including Selinexor Improved PFS in Relapsed/Refractory Myeloma

Once weekly combination treatment with selinexor, bortezomib, and dexamethasone (SVd) led to an approximately 4-month improvement in progression-free survival (PFS) compared with bortezomib plus...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title